VERICEL CORP (VCEL)
Health Care · Autologous Cell Therapy / Regenerative Medicine · NASDAQ
Vericel is a leader in advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI for cartilage repair and Epicel for severe burns.
What VERICEL CORP does
Vericel Corporation is a leading provider of advanced therapies focused on the sports medicine and severe burn care markets. The company develops and commercializes autologous cell therapy and specialty biologic products that use tissue engineering to regenerate skin and cartilage. Its primary products include MACI (autologous cellularized scaffold for knee cartilage defects, now including arthroscopic delivery option), Epicel (permanent skin replacement for severe burns), and NexoBrid (topical biological product for eschar removal in thermal burns, licensed from MediWound).
Themes: ["Cell therapy / autologous therapies","Regenerative medicine","Sports medicine orthopedics","Severe burn treatment","Cartilage repair / knee surgery","Skin regeneration"]
Fundamentals
- Price$48.31 as of 2026-07-09 close
- Market cap$2.4B as of 2026-07-10
- 1-year return+16.4% as of 2026-07-09 close
- P/E111.88 as of 2026-07-10
- Net margin+7.3% as of 2026-07-10
- Gross margin+74.8% as of 2026-07-10
- ROE+6.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+22.4% as of 2026-07-10
- Revenue CAGR (3y)+18.9% SEC XBRL
- Beta1.07 as of 2026-07-10
Key risks (from latest filing)
["Dependence on single supplier (Matricel GmbH) for critical ACI-Maix collagen membranes used in MACI manufacturing through 2030, with limited backup sourcing options if supplier fails","NexoBrid active ingredient (bromelain) sourced from Taiwan with supply chain concentration risk in a single geographic region","High SG&A expenses ($49.2M in Q1 2026) relative to gross profit ($49.3M), indicating ongoing challenges in achieving sustained profitability despite revenue growth of 22.45% YoY"]
Competitors & peers
- Arthrex
- Smith & Nephew
- Zimmer Biomet
- Baxter International
- Organogenesis
- Mimedx Group
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.